Gene polymorphisms as predictors of response to biological therapies in psoriasis patients

详细信息    查看全文

• 作者：Teresa Marí ; a Linares-Pineda^a ; ^{teresamaria712@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Marisa Cañ ; adas-Garre ; PhD^a ; ^{marisacgarre@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Antonio Sá ; nchez-Pozo ; PhD^b ; ¹ ; ^{sanchezpster@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Miguel Á ; ngel Calleja-Herná ; ndez^a ; ^{mangel.calleja.sspa@juntadeandalucia.es" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Adalimumab ; Infliximab ; Etarnecept ; Ustekinumab ; Psoriasis ; Drugs therapies ; Polymorphisms ; Effectiveness
• 刊名：Pharmacological Research
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：113
• 期：part_PA
• 页码：71-80
• 全文大小：524 K

文摘

Psoriasis is a chronic inflammatory autoimmune skin disease, characterized by the formation of erythematous scaly plaques on the skin and joints. The therapies for psoriasis are mainly symptomatic and sometimes with poor response. Response among patients is very variable, especially with biological drugs (adalimumab, etarnecept, infliximab and ustekimumab). This variability may be partly explained by the effect of different genetic backgrounds. This has prompted the investigation of many genes, such as FCGR3A, HLA, IL17F, IL23R, PDE3A-SLCO1C1, TNFα and other associated genes, as potential candidates to predict response to the different biological drugs used for the treatment of psoriasis. In this article, we will review the influence of gene polymorphisms investigated to date on response to biological drugs in psoriasis patients.